78 results on '"Ponzo M."'
Search Results
2. Early post-treatment changes in body composition parameters are associated with overall survival and need of transplantation in cirrhotic patients with HCC undergoing locoregional treatments
- Author
-
Parisse, S., primary, Mieli, M., additional, Ponzo, M., additional, Rocco, B., additional, Poli, E., additional, Pintore, A., additional, Ferri, F., additional, De Santis, A., additional, Lucatelli, P., additional, Corona, M., additional, Melandro, F., additional, Mennini, G., additional, Rossi, M., additional, Lai, Q., additional, and Corradini, S. Ginanni, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Molecular Hallmarks of Ischemia with Non-Obstructive Coronary Arteries: The “INOCA versus Obstructive CCS” Challenge
- Author
-
Bonanni, A., D'aiello, A., Pedicino, D., Di Sario, M., Vinci, R., Ponzo, M., Ciampi, P., Curto, D. L., Conte, C., Cribari, F., Canonico, F., Russo, G., Montone, R. A., Trani, C., Severino, A., Crea, F., Liuzzo, G., Bonanni A., Pedicino D., Di Sario M., Vinci R., Ponzo M., Ciampi P., Conte C., Cribari F., Canonico F. (ORCID:0000-0001-6936-4548), Montone R. A., Trani C. (ORCID:0000-0001-9777-013X), Severino A., Crea F. (ORCID:0000-0001-9404-8846), Liuzzo G. (ORCID:0000-0002-5714-0907), Bonanni, A., D'aiello, A., Pedicino, D., Di Sario, M., Vinci, R., Ponzo, M., Ciampi, P., Curto, D. L., Conte, C., Cribari, F., Canonico, F., Russo, G., Montone, R. A., Trani, C., Severino, A., Crea, F., Liuzzo, G., Bonanni A., Pedicino D., Di Sario M., Vinci R., Ponzo M., Ciampi P., Conte C., Cribari F., Canonico F. (ORCID:0000-0001-6936-4548), Montone R. A., Trani C. (ORCID:0000-0001-9777-013X), Severino A., Crea F. (ORCID:0000-0001-9404-8846), and Liuzzo G. (ORCID:0000-0002-5714-0907)
- Abstract
Up to 4 million patients with signs of myocardial ischemia have no obstructive coronary artery disease (CAD). The absence of precise guidelines for diagnosis and treatment in non-obstructive CAD encourages the scientific community to fill the gap knowledge, to provide non-invasive and less expensive diagnostic tools. The aim of our study was to explore the biological profile of Ischemia with Non-Obstructive Coronary Arteries (INOCA) patients with microvascular dysfunction compared to patients presenting with obstructive chronic coronary syndrome (ObCCS) in order to find specific hallmarks of each clinical condition. We performed a gene expression array from peripheral blood mononuclear cells (PBMCs) isolated from INOCA (n = 18) and ObCCS (n = 20) patients. Our results showed a significantly reduced gene expression of molecules involved in cell adhesion, signaling, vascular motion, and inflammation in INOCA as compared to the ObCCS group. In detail, we found lower expression of Platelet and Endothelial Cell Adhesion Molecule 1 (CD31, p < 0.0001), Intercellular Adhesion Molecule-1 (ICAM1, p = 0.0004), Tumor Necrosis Factor (TNF p = 0.0003), Transferrin Receptor (TFRC, p = 0.002), and Vascular Endothelial Growth Factor A (VEGFA, p = 0.0006) in the INOCA group compared with ObCCS. Meanwhile, we observed an increased expression of Hyaluronidase (HYAL2, p < 0.0001) in INOCA patients in comparison to ObCCS. The distinct expression of molecular biomarkers might allow an early and non-invasive differential diagnosis between ObCCS and INOCA, improving clinical management and treatment options, in the era of personalized medicine.
- Published
- 2022
4. Impact of the Tumor microenvironment on the activity of Chimeric Antigen Receptor (CAR) T Cells in B-cell precursor Acute Lymphoblastic Leukemia (B-ALL)
- Author
-
Ponzo, M, Gaipa, Giuseppe, PONZO, MARIANNA, Ponzo, M, Gaipa, Giuseppe, and PONZO, MARIANNA
- Abstract
La leucemia linfoblastica acuta a cellule B (B ALL) rappresenta il tumore più comune nei bambini. Recenti progressi hanno permesso alla maggioranza dei pazienti di ottenere una remissione completa.Un numero sostanziale di pazienti recidiva e un nuovo trattamento per questa categoriarappresenta un'esigenza clinica. La terapia cellulare con cellule CAR fornisce un bersaglio più specifico ed efficace delle cellule leucemiche.Le CAR sono recettori sintetici che combinano la specificità dell'antigene degli anticorpi con le funzioni di effettore delle cellule T.Nel nostro centro,abbiamo studiato l'uso dell'ingegneria non virale su una popolazione di cellule T allogeniche generate secondo il protocollo di differenziazione delle cellule CIK come alternativa alle convenzionali cellule CAR ingegnerizzate con vettori virali. Questa popolazione caratterizzata dall'arricchimento di cellule CD3+CD56+ citotossiche e da un elevato profilo di sicurezza. Inoltre, il protocollo di espansione è semplice, conforme alle regole GMPed economicamente vantaggioso, rendendole una fonte cellulare adatta per l'ingegneria CAR.Il nostro gruppo ha precedentemente ottimizzato una piattaforma non virale di trasposoni Sleeping Beauty (SB) per reindirizzare le cellule CIK con diversi CAR, ottenendo un'espressione stabile ed efficiente, elevata vitalità e espansione in vitro con un'unica fase di stimolazione. Il sistema è costituito da due elementi, il plasmide trasposone contenente il transgene di interesse e la trasposasi che media l'integrazione genomica stabile attraverso un meccanismo di taglia e incolla. Oltre al SB, altri recenti approcci non virali, tra cui il trasposone piggyback, l'utilizzo di mRNA, i nanocarrier di DNA a base lipidica e polimerica e i nanovettori, iniziano a essere applicati negli studi clinici emergenti. Qui, forniamo un'ampia panoramica di questi metodi innovativi e privi di virus per l'ingegneria delle cellule T e discutiamo la loro sicurezza ed efficacia. Inoltre, B cell Acute Lymphoblastic Leukemia (B ALL) represents the most common cancer in children. Recent advances in treatment protocols allowedthe vast majorityof patients to achieve complete remission. However, a substantial number of patients relapsesandnew treatment for this category of patients represent a clinical need.Adoptive Cell Therapy with Chimeric Antigen Receptor (CAR)T cellsprovides a more specific and effective target of leukemic cells.CAR molecules are synthetic receptors, which combine the antigen specificity of antibodies with T-cell effector functions.In our center,we investigatedthe use of non-viral engineering of an allogeneicT-cell population generated according to cytokine-induced killer (CIK) cell protocol of differentiation as alternative to conventional patient-derived CAR T cells engineered with viral vectors. This population is characterized by the enrichment of cytotoxic CD3+CD56+ cells and a high profile of safety, with minimal occurrence of graft-versus-host disease after allogeneic CIK infusion in leukemic patients. Moreover, CIK cell expansion protocol is easy, Good Manufacturing Practices compliant and cost-effective, making CIK cells a suitable cell source for CAR engineering.Our group has previously developed and optimized a non-viral Sleeping Beauty (SB) transposon platform to redirect CIK cells with different CARs, obtainingstable and efficient CAR expression, high viability and in vitro expansion with a single stimulation step.SB system consists of two elements, the transposon plasmidcontaining the transgene of interest, and the transposase which mediates stable genomic integration through a “cut-and-paste” mechanism. This approach allows to overcome the main issues associated with viral vectors, such as potential high manufacturing costs, regulatory hindrances and scale-up complexities.Othernon-viral approaches, including thepiggyback transposon, the utilization of mRNA, Lipid-based and Polymer-based DNA nanocarriers,and nanovectors
- Published
- 2023
5. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
- Author
-
Morosi, L, Matteo, C, Ceruti, T, Giordano, S, Ponzo, M, Frapolli, R, Zucchetti, M, Davoli, E, D’Incalci, M, Ubezio, P, Morosi L., Matteo C., Ceruti T., Giordano S., Ponzo M., Frapolli R., Zucchetti M., Davoli E., D’incalci M., Ubezio P., Morosi, L, Matteo, C, Ceruti, T, Giordano, S, Ponzo, M, Frapolli, R, Zucchetti, M, Davoli, E, D’Incalci, M, Ubezio, P, Morosi L., Matteo C., Ceruti T., Giordano S., Ponzo M., Frapolli R., Zucchetti M., Davoli E., D’incalci M., and Ubezio P.
- Abstract
Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel.Methods: Different inorganic nanoparticles were tested as matrices to visualize the PARP inhibitors (PARPi) niraparib and olaparib. Normalization by deuterated internal standard and a custom preprocessing pipeline were applied to achieve a reliable single pixel quantification of the two drugs in human ovarian tumors from treated mice.Results: A quantitative method to visualize niraparib and olaparib in tumor tissue of treated mice was set up and validated regarding precision, accuracy, linearity, repeatability and limit of detection. The different tumor penetration of the two drugs was visualized by MSI and confirmed by LC-MS/MS, indicating the homogeneous distribution and higher tumor exposure reached by niraparib compared to olaparib. On the other hand, niraparib distribution was heterogeneous in an ovarian tumor model overexpressing the multidrug resistance protein P-gp, a possible cause of resistance to PARPi.Conclusions: The current work highlights for the first time quantitative distribution of PAPRi in tumor tissue. The different tumor distribution of niraparib and olaparib could have important clinical implications. These data confirm the validity of MSI for spatial quantitative measurement of drug distribution providing fundamental information for pharmacokinetic studies, drug discovery and the study of resistance mechanisms.
- Published
- 2020
6. The Past, Present, and Future of Non-Viral CAR T Cells
- Author
-
Moretti, A, Ponzo, M, Nicolette, C, Tcherepanova, I, Biondi, A, Magnani, C, Moretti, Alex, Ponzo, Marianna, Nicolette, Charles A, Tcherepanova, Irina Y, Biondi, Andrea, Magnani, Chiara F, Moretti, A, Ponzo, M, Nicolette, C, Tcherepanova, I, Biondi, A, Magnani, C, Moretti, Alex, Ponzo, Marianna, Nicolette, Charles A, Tcherepanova, Irina Y, Biondi, Andrea, and Magnani, Chiara F
- Abstract
Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology that has revolutionized the way we conceive immunotherapy. The impressive clinical results of complete and prolonged response in refractory and relapsed diseases have shifted the landscape of treatment for hematological malignancies, particularly those of lymphoid origin, and opens up new possibilities for the treatment of solid neoplasms. However, the widening use of cell therapy is hampered by the accessibility to viral vectors that are commonly used for T cell transfection. In the era of messenger RNA (mRNA) vaccines and CRISPR/Cas (clustered regularly interspaced short palindromic repeat–CRISPR-associated) precise genome editing, novel and virus-free methods for T cell engineering are emerging as a more versatile, flexible, and sustainable alternative for next-generation CAR T cell manufacturing. Here, we discuss how the use of non-viral vectors can address some of the limitations of the viral methods of gene transfer and allow us to deliver genetic information in a stable, effective and straightforward manner. In particular, we address the main transposon systems such as Sleeping Beauty (SB) and piggyBac (PB), the utilization of mRNA, and innovative approaches of nanotechnology like Lipid-based and Polymer-based DNA nanocarriers and nanovectors. We also describe the most relevant preclinical data that have recently led to the use of non-viral gene therapy in emerging clinical trials, and the related safety and efficacy aspects. We will also provide practical considerations for future trials to enable successful and safe cell therapy with non-viral methods for CAR T cell generation.
- Published
- 2022
7. Monocyte-Platelet Aggregates Triggered by CD31 Molecule in Non-ST Elevation Myocardial Infarction: Clinical Implications in Plaque Rupture
- Author
-
Vinci, Ramona, Pedicino, Daniela, Bonanni, Alice, D'Aiello, A., Pisano, Eugenia, Ponzo, Myriana, Severino, Anna, Ciampi, Pellegrino, Canonico, Francesco, Russo, Giulio, Di Sario, Marianna, Vergallo, Rocco, Filomia, Simone, Montone, Rocco Antonio, Flego, Davide, Stefanini, L., Piacentini, Roberto, Conte, C., Cribari, Francesco, Massetti, Massimo, Crea, Filippo, Liuzzo, Giovanna, Vinci R., Pedicino D., Bonanni A., Pisano E., Ponzo M., Severino A., Ciampi P., Canonico F. (ORCID:0000-0001-6936-4548), Russo G., Di Sario M., Vergallo R., Filomia S., Montone R. A., Flego D., Piacentini R. (ORCID:0000-0003-4215-1643), Cribari F., Massetti M. (ORCID:0000-0002-7100-8478), Crea F. (ORCID:0000-0001-9404-8846), Liuzzo G. (ORCID:0000-0002-5714-0907), Vinci, Ramona, Pedicino, Daniela, Bonanni, Alice, D'Aiello, A., Pisano, Eugenia, Ponzo, Myriana, Severino, Anna, Ciampi, Pellegrino, Canonico, Francesco, Russo, Giulio, Di Sario, Marianna, Vergallo, Rocco, Filomia, Simone, Montone, Rocco Antonio, Flego, Davide, Stefanini, L., Piacentini, Roberto, Conte, C., Cribari, Francesco, Massetti, Massimo, Crea, Filippo, Liuzzo, Giovanna, Vinci R., Pedicino D., Bonanni A., Pisano E., Ponzo M., Severino A., Ciampi P., Canonico F. (ORCID:0000-0001-6936-4548), Russo G., Di Sario M., Vergallo R., Filomia S., Montone R. A., Flego D., Piacentini R. (ORCID:0000-0003-4215-1643), Cribari F., Massetti M. (ORCID:0000-0002-7100-8478), Crea F. (ORCID:0000-0001-9404-8846), and Liuzzo G. (ORCID:0000-0002-5714-0907)
- Abstract
Despite the recent innovations in cardiovascular care, atherothrombosis is still a major complication of acute coronary syndromes (ACS). We evaluated the involvement of the CD31 molecule in thrombotic risk through the formation of monocyte-platelet (Mo-Plt) aggregates in patients with ACS with no-ST-segment elevation myocardial infarction (NSTEMI) on top of dual anti-platelet therapy (DAPT). We enrolled 19 control (CTRL) subjects, 46 stable angina (SA), and 86 patients with NSTEMI, of which, 16 with Intact Fibrous Cap (IFC) and 19 with Ruptured Fibrous Cap (RFC) as assessed by the Optical Coherence Tomography (OCT). The expression of CD31 on monocytes and platelets was measured. Following the coronary angiography, 52 NSTEMIs were further stratified according to thrombus grade (TG) evaluation. Finally, a series of ex vivo experiments verified whether the CD31 participates in Mo-Plt aggregate formation. In patients with NSTEMI, CD31 was reduced on monocytes and was increased on platelets, especially in NSTEMI presented with RFC plaques compared to those with IFC lesions, and in patients with high TG compared to those with zero/low TG. Ex vivo experiments documented an increase in Mo-Plt aggregates among NSTEMI, which significantly decreased after the CD31 ligation, particularly in patients with RFC plaques. In NSTEMI, CD31 participates in Mo-Plt aggregate formation in spite of optimal therapy and DAPT, suggesting the existence of alternative thrombotic pathways, as predominantly displayed in patients with RFC.
- Published
- 2022
8. Takotsubo syndrome: a way to reach a straightforward diagnosis
- Author
-
Bonanni, A, primary, Pedicino, D, additional, Vinci, R, additional, D'Aiello, A, additional, Ponzo, M, additional, Ciampi, P, additional, Pisano, E, additional, Canonico, F, additional, Di Sario, M, additional, Conte, C, additional, Cribari, F, additional, Grimaldi, M C, additional, Severino, A, additional, Crea, F, additional, and Liuzzo, G, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Platelet hyaluronidase 2 enrichment in acute coronary syndromes: a conceivable role in monocyte-platelet aggregate formation
- Author
-
Vinci, Ramona, Pedicino, Daniela, D'Aiello, A., Ciampi, Pellegrino, Ponzo, Myriana, Bonanni, Alice, Russo, G., Montone, Rocco Antonio, Massetti, Massimo, Crea, Filippo, Liuzzo, Giovanna, Vinci R., Pedicino D., Ciampi P., Ponzo M., Bonanni A., Montone R. A., Massetti M. (ORCID:0000-0002-7100-8478), Crea F. (ORCID:0000-0001-9404-8846), Liuzzo G. (ORCID:0000-0002-5714-0907), Vinci, Ramona, Pedicino, Daniela, D'Aiello, A., Ciampi, Pellegrino, Ponzo, Myriana, Bonanni, Alice, Russo, G., Montone, Rocco Antonio, Massetti, Massimo, Crea, Filippo, Liuzzo, Giovanna, Vinci R., Pedicino D., Ciampi P., Ponzo M., Bonanni A., Montone R. A., Massetti M. (ORCID:0000-0002-7100-8478), Crea F. (ORCID:0000-0001-9404-8846), and Liuzzo G. (ORCID:0000-0002-5714-0907)
- Abstract
Acute Coronary Syndromes (ACS) with plaque erosion display dysregulated hyaluronan metabolism, with increased hyaluronidase-2 (HYAL2) expression. However, the expression and the role of this enzyme on platelets has never been explored. We evaluated the platelet’s HYAL2 (pltHYAL2) levels on I) stable angina (SA) and II) ACS patients, furtherly sub-grouped in Intact-Fibrous-Cap (IFC) and Ruptured-Fibrous-Cap (RFC), according to Optical Coherence Tomography. We assessed the HYAL2 role through an in vitro model setting of co-cultured monocytes and platelets, before and after treatment with low-molecular-weight hyaluronic acid (HA) as pro-inflammatory stimulus and with or without HYAL2-antibody to inhibit HYAL2 activity. ACS patients exhibit higher pltHYAL2 levels comparing to SA, with the higher expression for IFC group. The addition of HYAL2-antibody significantly reduced the percentage of monocyte-platelet binding, suggesting that pltHYAL2 enrichment at the site of the culprit lesion is a key mediator in the systemic thrombo-inflammatory status of ACS presenting with plaque erosion.
- Published
- 2021
10. Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients
- Author
-
Capasso Palmiero, U, Morosi, L, Lupi, M, Ponzo, M, Frapolli, R, Zucchetti, M, Ubezio, P, Morbidelli, M, D'Incalci, M, Bello, E, Moscatelli, D, Capasso Palmiero U., Morosi L., Lupi M., Ponzo M., Frapolli R., Zucchetti M., Ubezio P., Morbidelli M., D'Incalci M., Bello E., Moscatelli D., Capasso Palmiero, U, Morosi, L, Lupi, M, Ponzo, M, Frapolli, R, Zucchetti, M, Ubezio, P, Morbidelli, M, D'Incalci, M, Bello, E, Moscatelli, D, Capasso Palmiero U., Morosi L., Lupi M., Ponzo M., Frapolli R., Zucchetti M., Ubezio P., Morbidelli M., D'Incalci M., Bello E., and Moscatelli D.
- Abstract
The advent of nanotechnology in medicine has allowed to eliminate the toxic excipients that are often necessary to formulate lipophilic drugs in clinics. An example is paclitaxel, one of the most important chemotherapeutic drugs developed so far, where the Cremophor EL has been eliminated in the Genexol and Abraxane formulations. However, the complex procedures to synthesize these formulations hamper their cost-effective use and, in turn, their distribution among the patient population. For this reason, a simplified method to formulate this drug directly at the bed of the patient has been adopted. It requires only the use of a syringe and it starts from a native dry amphiphilic biodegradable and biocompatible block-copolymer obtained via the combination of the reversible addition–fragmentation chain transfer polymerization and ring-opening polymerization. In this way, a novel paclitaxel formulation with the same drug pharmacological properties, but without the use of the Cremophor EL, can be produced. In addition, as long as these nanoparticles are engineered to act as solubility enhancers, a lower burden for its approval from the pharmaceutical regulatory agencies is also expected.
- Published
- 2018
11. Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin
- Author
-
Capasso Palmiero, U, Morosi, L, Bello, E, Ponzo, M, Frapolli, R, Matteo, C, Ferrari, M, Zucchetti, M, Minoli, L, De Maglie, M, Romanelli, P, Morbidelli, M, D'Incalci, M, Moscatelli, D, Capasso Palmiero U., Morosi L., Bello E., Ponzo M., Frapolli R., Matteo C., Ferrari M., Zucchetti M., Minoli L., De Maglie M., Romanelli P., Morbidelli M., D'Incalci M., Moscatelli D., Capasso Palmiero, U, Morosi, L, Bello, E, Ponzo, M, Frapolli, R, Matteo, C, Ferrari, M, Zucchetti, M, Minoli, L, De Maglie, M, Romanelli, P, Morbidelli, M, D'Incalci, M, Moscatelli, D, Capasso Palmiero U., Morosi L., Bello E., Ponzo M., Frapolli R., Matteo C., Ferrari M., Zucchetti M., Minoli L., De Maglie M., Romanelli P., Morbidelli M., D'Incalci M., and Moscatelli D.
- Abstract
The improvement of the pharmacological profile of lipophilic drug formulations is one of the main successes achieved using nanoparticles (NPs) in medicine. However, the complex synthesis procedure and numerous post-processing steps hamper the cost-effective use of these formulations. In this work, an approach which requires only a syringe to produce self-assembling biodegradable and biocompatible poly(caprolactone)-based NPs is developed. The effective synthesis of monodisperse NPs has been made possible by the optimization of the block-copolymer synthesized via a combination of ring opening polymerization and reversible addition-fragmentation chain transfer polymerization. These NPs can be used to formulate lipophilic drugs that are barely soluble in water, such as trabectedin, a potent anticancer therapeutic. Its biodistribution and antitumor activity have been compared with the commercially available formulation Yondelis®. The results indicate that this trabectedin NP formulation performs with the same antitumor activity as Yondelis®, but does not have the drawback of severe local vascular toxicity in the injection site.
- Published
- 2018
12. Non invasive ventilation and right ventricle function in cardiogenic pulmonary edema: an echocardiographic perspective to select the "right" ventilatory support
- Author
-
Pedicino, D, primary, Angelini, A, additional, Russo, G, additional, D"aiello, A, additional, Rocco, E, additional, Ciampi, P, additional, Ponzo, M, additional, Graziani, F, additional, Locorotondo, G, additional, Sanna, T, additional, Rebuzzi, AG, additional, Lombardo, A, additional, Massetti, M, additional, Liuzzo, G, additional, and Crea, F, additional
- Published
- 2021
- Full Text
- View/download PDF
13. Plaque instability in acute coronary syndromes: a possible pathogenic role of gut microbial communities
- Author
-
Pisano, E, primary, Severino, A, additional, Bugli, F, additional, Pedicino, D, additional, Paroni Sterbini, F, additional, Martini, C, additional, Vinci, R, additional, Canonico, F, additional, Bonanni, A, additional, D'Aiello, A, additional, Ciampi, P, additional, Ponzo, M, additional, Sanguinetti, M, additional, Crea, F, additional, and Liuzzo, G, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Meta-inflammation in monocytes of patients with Acute Coronary Syndrome
- Author
-
Canonico, F, primary, Vinci, R, additional, Pedicino, D, additional, Pisano, E, additional, Ciampi, P, additional, Bonanni, A, additional, Ponzo, M, additional, D'Aiello, A, additional, Di Sario, M, additional, Severino, A, additional, D'Amario, D, additional, Niccoli, G, additional, Biasucci, L.M, additional, Crea, F, additional, and Liuzzo, G, additional
- Published
- 2020
- Full Text
- View/download PDF
15. Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas
- Author
-
Frapolli, R, Bello, E, Ponzo, M, Craparotta, I, Mannarino, L, Ballabio, S, Marchini, S, Carrassa, L, Ubezio, P, Porcu, L, Brich, S, Sanfilippo, R, Casali, P, Gronchi, A, Pilotti, S, D'Incalci, M, Frapolli, Roberta, Bello, Ezia, Ponzo, Marianna, Craparotta, Ilaria, Mannarino, Laura, Ballabio, Sara, Marchini, Sergio, Carrassa, Laura, Ubezio, Paolo, Porcu, Luca, Brich, Silvia, Sanfilippo, Roberta, Casali, Paolo Giovanni, Gronchi, Alessandro, Pilotti, Silvana, D'Incalci, Maurizio, Frapolli, R, Bello, E, Ponzo, M, Craparotta, I, Mannarino, L, Ballabio, S, Marchini, S, Carrassa, L, Ubezio, P, Porcu, L, Brich, S, Sanfilippo, R, Casali, P, Gronchi, A, Pilotti, S, D'Incalci, M, Frapolli, Roberta, Bello, Ezia, Ponzo, Marianna, Craparotta, Ilaria, Mannarino, Laura, Ballabio, Sara, Marchini, Sergio, Carrassa, Laura, Ubezio, Paolo, Porcu, Luca, Brich, Silvia, Sanfilippo, Roberta, Casali, Paolo Giovanni, Gronchi, Alessandro, Pilotti, Silvana, and D'Incalci, Maurizio
- Abstract
Purpose: This study was aimed at investigating whether the PPARg agonist pioglitazone—given in combination with trabectedin—is able to reactivate adipocytic differentiation in myxoid liposarcoma (MLS) patient-derived xenografts, overcoming resistance to trabectedin. Experimental Design: The antitumor and biological effects of trabectedin, pioglitazone, and the combination of the two drugs were investigated in nude mice bearing well-characterized MLS xenografts representative of innate or acquired resistance against trabectedin. Pioglitazone and trabectedin were given by daily oral and weekly i.v. administrations, respectively. Molecular studies were performed by using microarrays approach, real-time PCR, and Western blotting. Results: We found that the resistance of MLS against trabectedin is associated with the lack of activation of adipogenesis. The PPARg agonist pioglitazone reactivated adipogenesis, assessed by histologic and gene pathway analyses. Pioglitazone was well tolerated and did not increase the toxicity of trabectedin. The ability of pioglitazone to reactivate adipocytic differentiation was observed by morphologic examination, and it is consistent with the increased expression of genes such as ADIPOQ implicated in the adipogenesis process. The determination of adiponectin by Western blotting constitutes a good and reliable biomarker related to MLS adipocytic differentiation. Conclusions: The finding that the combination of pioglitazone and trabectedin induces terminal adipocytic differentiation of some MLSs with the complete pathologic response and cure of tumor-bearing mice provides a strong rationale to test the combination of trabectedin and pioglitazone in patients with MLS.
- Published
- 2019
16. P1692Increased expression of CD31 on platelets from patients with Non-ST segment Elevation Myocardial Infarction and its role in platelets-monocytes interaction
- Author
-
Vinci, R, primary, Pedicino, D, additional, Pisano, E, additional, Flego, D, additional, Giglio, A F, additional, Trotta, F, additional, Lucci, C, additional, Ruggio, A, additional, Ponzo, M, additional, D'Aiello, A, additional, Canonico, F, additional, Severino, A, additional, Biasucci, L M, additional, Liuzzo, G, additional, and Crea, F, additional
- Published
- 2018
- Full Text
- View/download PDF
17. RAPPORT DE LA COMMISSION POUR LA FORMATION DES PSYCHOTECHNICIENS
- Author
-
Cook, P. H., Elmgren, J., Frisby, C. B., Geldard, F. A., Pacaud, S., Ponzo, M., and Rey, A.
- Published
- 1952
18. FERRUCCIO BANISSONI: (Trieste 1888 -Rome 1952)
- Author
-
Piéron, H. and Ponzo, M.
- Published
- 1952
19. ORGANISATION DU VOYAGE ET DU SÉJOUR DES CONGRESSISTES A PARIS
- Author
-
Ponzo, M.
- Published
- 1952
20. Variazione terminologica e approcci terminografici nell’ambito delle energie rinnovabili: riflessioni sul progetto IATE- Lexecolo
- Author
-
Rossi, Micaela and Ponzo, M. E.
- Published
- 2012
21. Illusioni nei nostri giudizi sul numero
- Author
-
Ponzo, M., primary
- Published
- 1925
- Full Text
- View/download PDF
22. Significato di modificazioni respiratone durante lo svolgersi dell’attività del pensiero
- Author
-
Ponzo, M., primary
- Published
- 1925
- Full Text
- View/download PDF
23. Obituary to Frederico Kiesow, 1858–1941
- Author
-
Ponzo, M.
- Published
- 1941
24. [Behavior of the principal serum enzyme activities in the course of hepatobiliary diseases]
- Author
-
enrico papini, Pagano A, Panunzi C, Ponzo M, Mc, Rovagna, and Picardi R
- Subjects
Leucyl Aminopeptidase ,Cholelithiasis ,Biliary Tract Diseases ,Liver Diseases ,Humans ,Alanine Transaminase ,Gallbladder Neoplasms ,Aspartate Aminotransferases ,Gallbladder Diseases ,gamma-Glutamyltransferase ,Alkaline Phosphatase ,Oxidoreductases ,Biliary Dyskinesia - Published
- 1978
25. Ueber einige Beruhrungstauschungen
- Author
-
Jenkins, W., primary, Kiesow, F., additional, and Ponzo, M., additional
- Published
- 1908
- Full Text
- View/download PDF
26. Impact of the Tumor microenvironment on the activity of Chimeric Antigen Receptor (CAR) T Cells in B-cell precursor Acute Lymphoblastic Leukemia (B-ALL)
- Author
-
PONZO, MARIANNA, Ponzo, M, and Gaipa, Giuseppe
- Subjects
CAR T ,immunosuppression ,MED/15 - MALATTIE DEL SANGUE ,TME ,B-ALL ,immunosoppressione ,microambiente ,scRNAseq - Abstract
La leucemia linfoblastica acuta a cellule B (B ALL) rappresenta il tumore più comune nei bambini. Recenti progressi hanno permesso alla maggioranza dei pazienti di ottenere una remissione completa.Un numero sostanziale di pazienti recidiva e un nuovo trattamento per questa categoriarappresenta un'esigenza clinica. La terapia cellulare con cellule CAR fornisce un bersaglio più specifico ed efficace delle cellule leucemiche.Le CAR sono recettori sintetici che combinano la specificità dell'antigene degli anticorpi con le funzioni di effettore delle cellule T.Nel nostro centro,abbiamo studiato l'uso dell'ingegneria non virale su una popolazione di cellule T allogeniche generate secondo il protocollo di differenziazione delle cellule CIK come alternativa alle convenzionali cellule CAR ingegnerizzate con vettori virali. Questa popolazione caratterizzata dall'arricchimento di cellule CD3+CD56+ citotossiche e da un elevato profilo di sicurezza. Inoltre, il protocollo di espansione è semplice, conforme alle regole GMPed economicamente vantaggioso, rendendole una fonte cellulare adatta per l'ingegneria CAR.Il nostro gruppo ha precedentemente ottimizzato una piattaforma non virale di trasposoni Sleeping Beauty (SB) per reindirizzare le cellule CIK con diversi CAR, ottenendo un'espressione stabile ed efficiente, elevata vitalità e espansione in vitro con un'unica fase di stimolazione. Il sistema è costituito da due elementi, il plasmide trasposone contenente il transgene di interesse e la trasposasi che media l'integrazione genomica stabile attraverso un meccanismo di taglia e incolla. Oltre al SB, altri recenti approcci non virali, tra cui il trasposone piggyback, l'utilizzo di mRNA, i nanocarrier di DNA a base lipidica e polimerica e i nanovettori, iniziano a essere applicati negli studi clinici emergenti. Qui, forniamo un'ampia panoramica di questi metodi innovativi e privi di virus per l'ingegneria delle cellule T e discutiamo la loro sicurezza ed efficacia. Inoltre, la tesi si concentra sullo studio delle interazioni delle cellule T CAR anti-CD19 con il microambiente tumorale (TME) nella B-ALL e mira a identificare i fattori che influenzano l'attività e la potenza delle cellule T anti-CD19CAR e che inducono la resistenza ai farmaci. A questo scopo, abbiamo eseguito l'analisi trascrizionale di campioni di midollo osseo (BM) raccolti precocemente dopo l'infusione di cellule CAR-T mediante sequenziamento di RNA a singola cellula. Le analisi preliminari dei dati del laboratorio ematologico e della citometria a flusso condotte sul sangue periferico totale dei pazienti trattati con CAR T ci hanno portato a ipotizzare che le cellule CAR T nei pazienti affetti da B-ALL suscitino una risposta acuta che coinvolge sia l'immunità innata che quella adattativa, che viene poi regolata attivamente. Sono stati osservati cambiamenti distinti nella composizione del BM dopo il trattamento con cellule CAR T, nonché un aumento significativo della frazione di cellule mieloidi e NK e un arricchimento delle cellule soppressorie di derivazione mieloide, rispetto al campione alla ricaduta. L'analisi dell'arricchimento dei set di geni tra i singoli tipi di cellule utilizzando il set Hallmark ha mostrato un arricchimento significativo per il profilo di espressione genica associato alla risposta IFN-α e IFN-γ, all'ipossia, all'IL6JAKSTAT3 e alla segnalazione WNT β-catenina. Parallelamente, è stato osservato un aumento della popolazione di cellule CD8 esauste dopo l'infusione di cellule T CAR associato a IFNα e IFN-γ, IL2 STAT5 e segnalazione di Hedgehog. È in corso la convalida mediante citometria a flusso per confermare il coinvolgimento di vie quali TGFβ, ipossia e l'asse CCL2-CCR2 emerso dalla modellazione delle comunicazioni intercellulari.In conclusione l'attivazione mieloide mediata dalle cellule CAR T è associata a vie di disregolazione immunitaria che possono attenuare l'espansione delle CAR e antagonizzare gli effetti della terapia B cell Acute Lymphoblastic Leukemia (B ALL) represents the most common cancer in children. Recent advances in treatment protocols allowedthe vast majorityof patients to achieve complete remission. However, a substantial number of patients relapsesandnew treatment for this category of patients represent a clinical need.Adoptive Cell Therapy with Chimeric Antigen Receptor (CAR)T cellsprovides a more specific and effective target of leukemic cells.CAR molecules are synthetic receptors, which combine the antigen specificity of antibodies with T-cell effector functions.In our center,we investigatedthe use of non-viral engineering of an allogeneicT-cell population generated according to cytokine-induced killer (CIK) cell protocol of differentiation as alternative to conventional patient-derived CAR T cells engineered with viral vectors. This population is characterized by the enrichment of cytotoxic CD3+CD56+ cells and a high profile of safety, with minimal occurrence of graft-versus-host disease after allogeneic CIK infusion in leukemic patients. Moreover, CIK cell expansion protocol is easy, Good Manufacturing Practices compliant and cost-effective, making CIK cells a suitable cell source for CAR engineering.Our group has previously developed and optimized a non-viral Sleeping Beauty (SB) transposon platform to redirect CIK cells with different CARs, obtainingstable and efficient CAR expression, high viability and in vitro expansion with a single stimulation step.SB system consists of two elements, the transposon plasmidcontaining the transgene of interest, and the transposase which mediates stable genomic integration through a “cut-and-paste” mechanism. This approach allows to overcome the main issues associated with viral vectors, such as potential high manufacturing costs, regulatory hindrances and scale-up complexities.Othernon-viral approaches, including thepiggyback transposon, the utilization of mRNA, Lipid-based and Polymer-based DNA nanocarriers,and nanovectorshave recentlyentered the field and start to being applied in emerging clinical trials.Here, weprovidean extensiveoverview ofthesenovel and virus-freemethods for T-cell engineeringand discusstheir safetyand efficacy. Moreover, we focus onthe study of the interactions of anti-CD19 CAR T cells with the tumor microenvironment (TME) in B-ALL and aims atidentifying factors that influence the activity and potency of anti-CD19CAR T cells andinduce drugresistance. For this purpose, we performed transcriptional analysis of bone marrow (BM) samples collected at early time after CAR-T cell infusion by means of single-cell RNA sequencing. Preliminary analyses of the hematology laboratory and flow cytometry dataconducted on total peripheral bloodfrom CAR T treated patients led us to hypothesize that CAR T cells in B-ALL patients elicit an acuteresponse involving both innate and adaptive immunity which is then actively regulated. Distinct shifts in BM composition after CAR T-cell treatment were observed, as well as a significant increase in the fraction of myeloid and NK cells after infusion and enrichment of myeloid-derived suppressor cells, as compared to sample at relapse. Gene set enrichment analysis across individual cell types using the Hallmark gene set showed a significant enrichment for gene expression profile associated with IFN-α and IFN- response, hypoxia, IL6 JAK STAT3, and WNT β-catenin signaling. In parallel, an increase of CD8 exhausted cell population after CAR T-cell infusion was observed associated with IFNα and IFN-response, IL2 STAT5, and Hedgehog signalling.Validation by flow cytometry is ongoing to confirme involvement ofpathways ofsuch as TGF-β, Hypoxia and theCCL2-CCR2 axisemerged by modelling intercellular communications.In conclusion, CAR T-cellmediated myeloid activation are associated with pathways of immune dysregulation that may dampen CAR T cell expansion and antagonize the effects of the therapy.
- Published
- 2023
27. The Past, Present, and Future of Non-Viral CAR T Cells
- Author
-
Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara F. Magnani, Moretti, A, Ponzo, M, Nicolette, C, Tcherepanova, I, Biondi, A, and Magnani, C
- Subjects
Gene Editing ,transposon ,mRNA ,T-Lymphocytes ,Immunology ,Receptors, Antigen, T-Cell ,chimeric antigen receptor (CAR T) ,gene therapy ,Immunotherapy, Adoptive ,non-viral vector ,cancer therapy ,Immunology and Allergy ,immunotherapy ,RNA, Messenger ,adoptive cell transfer - Abstract
Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology that has revolutionized the way we conceive immunotherapy. The impressive clinical results of complete and prolonged response in refractory and relapsed diseases have shifted the landscape of treatment for hematological malignancies, particularly those of lymphoid origin, and opens up new possibilities for the treatment of solid neoplasms. However, the widening use of cell therapy is hampered by the accessibility to viral vectors that are commonly used for T cell transfection. In the era of messenger RNA (mRNA) vaccines and CRISPR/Cas (clustered regularly interspaced short palindromic repeat–CRISPR-associated) precise genome editing, novel and virus-free methods for T cell engineering are emerging as a more versatile, flexible, and sustainable alternative for next-generation CAR T cell manufacturing. Here, we discuss how the use of non-viral vectors can address some of the limitations of the viral methods of gene transfer and allow us to deliver genetic information in a stable, effective and straightforward manner. In particular, we address the main transposon systems such as Sleeping Beauty (SB) and piggyBac (PB), the utilization of mRNA, and innovative approaches of nanotechnology like Lipid-based and Polymer-based DNA nanocarriers and nanovectors. We also describe the most relevant preclinical data that have recently led to the use of non-viral gene therapy in emerging clinical trials, and the related safety and efficacy aspects. We will also provide practical considerations for future trials to enable successful and safe cell therapy with non-viral methods for CAR T cell generation.
- Published
- 2022
28. Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas
- Author
-
Roberta Frapolli, Marianna Ponzo, Alessandro Gronchi, Roberta Sanfilippo, Maurizio D'Incalci, Laura Mannarino, Ilaria Craparotta, Silvana Pilotti, Sergio Marchini, Ezia Bello, Laura Carrassa, Sara Ballabio, Luca Porcu, Silvia Brich, Paolo Ubezio, Paolo G. Casali, Frapolli, R, Bello, E, Ponzo, M, Craparotta, I, Mannarino, L, Ballabio, S, Marchini, S, Carrassa, L, Ubezio, P, Porcu, L, Brich, S, Sanfilippo, R, Casali, P, Gronchi, A, Pilotti, S, and D'Incalci, M
- Subjects
0301 basic medicine ,Cancer Research ,Mice, Nude ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Adipocyte ,Antineoplastic Combined Chemotherapy Protocols ,Adipocytes ,medicine ,Animals ,Humans ,Hypoglycemic Agents ,Antineoplastic Agents, Alkylating ,Trabectedin ,Myxoid liposarcoma ,Pioglitazone ,Adiponectin ,business.industry ,Cell Differentiation ,medicine.disease ,Xenograft Model Antitumor Assays ,Liposarcoma, Myxoid ,PPAR gamma ,Blot ,030104 developmental biology ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Adipogenesis ,030220 oncology & carcinogenesis ,Cancer research ,Biomarker (medicine) ,Female ,business ,pioglitazone trabectedin adipocytic differentiation overcoming resistance adipogenesis ,medicine.drug - Abstract
Purpose: This study was aimed at investigating whether the PPARγ agonist pioglitazone—given in combination with trabectedin—is able to reactivate adipocytic differentiation in myxoid liposarcoma (MLS) patient-derived xenografts, overcoming resistance to trabectedin. Experimental Design: The antitumor and biological effects of trabectedin, pioglitazone, and the combination of the two drugs were investigated in nude mice bearing well-characterized MLS xenografts representative of innate or acquired resistance against trabectedin. Pioglitazone and trabectedin were given by daily oral and weekly i.v. administrations, respectively. Molecular studies were performed by using microarrays approach, real-time PCR, and Western blotting. Results: We found that the resistance of MLS against trabectedin is associated with the lack of activation of adipogenesis. The PPARγ agonist pioglitazone reactivated adipogenesis, assessed by histologic and gene pathway analyses. Pioglitazone was well tolerated and did not increase the toxicity of trabectedin. The ability of pioglitazone to reactivate adipocytic differentiation was observed by morphologic examination, and it is consistent with the increased expression of genes such as ADIPOQ implicated in the adipogenesis process. The determination of adiponectin by Western blotting constitutes a good and reliable biomarker related to MLS adipocytic differentiation. Conclusions: The finding that the combination of pioglitazone and trabectedin induces terminal adipocytic differentiation of some MLSs with the complete pathologic response and cure of tumor-bearing mice provides a strong rationale to test the combination of trabectedin and pioglitazone in patients with MLS.
- Published
- 2019
29. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
- Author
-
Tommaso Ceruti, Roberta Frapolli, Massimo Zucchetti, Silvia Giordano, Marianna Ponzo, Lavinia Morosi, Paolo Ubezio, Maurizio D'Incalci, Cristina Matteo, Enrico Davoli, Morosi, L, Matteo, C, Ceruti, T, Giordano, S, Ponzo, M, Frapolli, R, Zucchetti, M, Davoli, E, D’Incalci, M, and Ubezio, P
- Subjects
Indazoles ,PARPi ,Mice, Nude ,Antineoplastic Agents ,Poly(ADP-ribose) Polymerase Inhibitors ,Applied Microbiology and Biotechnology ,Mass Spectrometry ,Piperazines ,Mass spectrometry imaging ,Olaparib ,Mice ,03 medical and health sciences ,Ovarian tumor ,chemistry.chemical_compound ,Piperidines ,Pharmacokinetics ,Limit of Detection ,Drug distribution ,Animals ,Distribution (pharmacology) ,Molecular Biology ,Ecology, Evolution, Behavior and Systematics ,030304 developmental biology ,Ions ,Ovarian Neoplasms ,0303 health sciences ,Drug discovery ,Reproducibility of Results ,Cell Biology ,Quantitative determination ,Disease Models, Animal ,Targeted mass spectrometry ,chemistry ,Cancer research ,Phthalazines ,Female ,Chromatography, Liquid ,Research Paper ,Developmental Biology - Abstract
Rationale: Optimal intratumor distribution of an anticancer drug is fundamental to reach an active concentration in neoplastic cells, ensuring the therapeutic effect. Determination of drug concentration in tumor homogenates by LC-MS/MS gives important information about this issue but the spatial information gets lost. Targeted mass spectrometry imaging (MSI) has great potential to visualize drug distribution in the different areas of tumor sections, with good spatial resolution and superior specificity. MSI is rapidly evolving as a quantitative technique to measure the absolute drug concentration in each single pixel. Methods: Different inorganic nanoparticles were tested as matrices to visualize the PARP inhibitors (PARPi) niraparib and olaparib. Normalization by deuterated internal standard and a custom preprocessing pipeline were applied to achieve a reliable single pixel quantification of the two drugs in human ovarian tumors from treated mice. Results: A quantitative method to visualize niraparib and olaparib in tumor tissue of treated mice was set up and validated regarding precision, accuracy, linearity, repeatability and limit of detection. The different tumor penetration of the two drugs was visualized by MSI and confirmed by LC-MS/MS, indicating the homogeneous distribution and higher tumor exposure reached by niraparib compared to olaparib. On the other hand, niraparib distribution was heterogeneous in an ovarian tumor model overexpressing the multidrug resistance protein P-gp, a possible cause of resistance to PARPi. Conclusions: The current work highlights for the first time quantitative distribution of PAPRi in tumor tissue. The different tumor distribution of niraparib and olaparib could have important clinical implications. These data confirm the validity of MSI for spatial quantitative measurement of drug distribution providing fundamental information for pharmacokinetic studies, drug discovery and the study of resistance mechanisms.
- Published
- 2020
30. Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin
- Author
-
Massimo Morbidelli, Davide Moscatelli, Marianna Ponzo, Umberto Capasso Palmiero, Ezia Bello, Mariella Ferrari, Pierpaolo Romanelli, Lucia Minoli, Massimo Zucchetti, Marcella De Maglie, Lavinia Morosi, Maurizio D'Incalci, Cristina Matteo, Roberta Frapolli, Capasso Palmiero, U, Morosi, L, Bello, E, Ponzo, M, Frapolli, R, Matteo, C, Ferrari, M, Zucchetti, M, Minoli, L, De Maglie, M, Romanelli, P, Morbidelli, M, D'Incalci, M, and Moscatelli, D
- Subjects
Biodistribution ,Polymers ,Dispersity ,Pharmaceutical Science ,Mice, Nude ,02 engineering and technology ,010402 general chemistry ,01 natural sciences ,Ring-opening polymerization ,chemistry.chemical_compound ,Nanoparticle ,medicine ,Animals ,Tissue Distribution ,Polymer ,Antineoplastic Agents, Alkylating ,Trabectedin ,Biodegradable ,Nanoparticles ,Phlebitis ,Polycaprolactone ,Polyethylen glycol ,Vascular toxicity ,3003 ,Skin ,Animal ,technology, industry, and agriculture ,Water ,Chain transfer ,Liposarcoma ,021001 nanoscience & nanotechnology ,Combinatorial chemistry ,0104 chemical sciences ,Mice, Inbred C57BL ,chemistry ,Polymerization ,Solubility ,Phlebiti ,Female ,0210 nano-technology ,Caprolactone ,medicine.drug - Abstract
The improvement of the pharmacological profile of lipophilic drug formulations is one of the main successes achieved using nanoparticles (NPs) in medicine. However, the complex synthesis procedure and numerous post-processing steps hamper the cost-effective use of these formulations. In this work, an approach which requires only a syringe to produce self-assembling biodegradable and biocompatible poly(caprolactone)-based NPs is developed. The effective synthesis of monodisperse NPs has been made possible by the optimization of the block-copolymer synthesized via a combination of ring opening polymerization and reversible addition-fragmentation chain transfer polymerization. These NPs can be used to formulate lipophilic drugs that are barely soluble in water, such as trabectedin, a potent anticancer therapeutic. Its biodistribution and antitumor activity have been compared with the commercially available formulation Yondelis®. The results indicate that this trabectedin NP formulation performs with the same antitumor activity as Yondelis®, but does not have the drawback of severe local vascular toxicity in the injection site.
- Published
- 2017
31. Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients
- Author
-
Lavinia Morosi, Massimo Morbidelli, Paolo Ubezio, Marianna Ponzo, Davide Moscatelli, Umberto Capasso Palmiero, Ezia Bello, Massimo Zucchetti, Monica Lupi, Maurizio D'Incalci, Roberta Frapolli, Capasso Palmiero, U, Morosi, L, Lupi, M, Ponzo, M, Frapolli, R, Zucchetti, M, Ubezio, P, Morbidelli, M, D'Incalci, M, Bello, E, and Moscatelli, D
- Subjects
Materials Chemistry2506 Metals and Alloys ,Drug ,Paclitaxel ,Polymers and Plastics ,media_common.quotation_subject ,Excipient ,Bioengineering ,02 engineering and technology ,010402 general chemistry ,01 natural sciences ,Excipients ,Biomaterials ,chemistry.chemical_compound ,Nanoparticle ,Amphiphile ,Materials Chemistry ,medicine ,Drug Carrier ,media_common ,excipient ,Drug Carriers ,Chemistry ,Chain transfer ,drug delivery ,nanoparticles ,paclitaxel ,self-assembly ,Biotechnology ,021001 nanoscience & nanotechnology ,Combinatorial chemistry ,0104 chemical sciences ,Solubility ,Drug delivery ,Nanoparticles ,Nanomedicine ,0210 nano-technology ,Drug carrier ,medicine.drug - Abstract
The advent of nanotechnology in medicine has allowed to eliminate the toxic excipients that are often necessary to formulate lipophilic drugs in clinics. An example is paclitaxel, one of the most important chemotherapeutic drugs developed so far, where the Cremophor EL has been eliminated in the Genexol and Abraxane formulations. However, the complex procedures to synthesize these formulations hamper their cost-effective use and, in turn, their distribution among the patient population. For this reason, a simplified method to formulate this drug directly at the bed of the patient has been adopted. It requires only the use of a syringe and it starts from a native dry amphiphilic biodegradable and biocompatible block-copolymer obtained via the combination of the reversible addition–fragmentation chain transfer polymerization and ring-opening polymerization. In this way, a novel paclitaxel formulation with the same drug pharmacological properties, but without the use of the Cremophor EL, can be produced. In addition, as long as these nanoparticles are engineered to act as solubility enhancers, a lower burden for its approval from the pharmaceutical regulatory agencies is also expected.
- Published
- 2018
32. TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.
- Author
-
Debesset A, Pilon C, Meunier S, Cuelenaere-Bonizec O, Richer W, Thiolat A, Houppe C, Ponzo M, Magnan J, Caron J, Caudana P, Tosello Boari J, Baulande S, To NH, Salomon BL, Piaggio E, Cascone I, and Cohen JL
- Subjects
- Animals, Humans, Mice, Female, Male, Tumor Microenvironment, T-Cell Exhaustion, Receptors, Tumor Necrosis Factor, Type II metabolism, T-Lymphocytes, Regulatory immunology, Carcinoma, Pancreatic Ductal immunology, Carcinoma, Pancreatic Ductal drug therapy, Pancreatic Neoplasms immunology, Pancreatic Neoplasms drug therapy
- Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, highly resistant to standard chemotherapy and immunotherapy. Regulatory T cells (Tregs) expressing tumor necrosis factor α receptor 2 (TNFR2) contribute to immunosuppression in PDAC. Treg infiltration correlates with poor survival and tumor progression in patients with PDAC. We hypothesized that TNFR2 inhibition using a blocking monoclonal antibody (mAb) could shift the Treg-effector T cell balance in PDAC, thus enhancing antitumoral responses., Method: To support this hypothesis, we first described TNFR2 expression in a cohort of 24 patients with PDAC from publicly available single-cell analysis data. In orthotopic and immunocompetent mouse models of PDAC, we also described the immune environment of PDAC after immune cell sorting and single-cell analysis. The modifications of the immune environment before and after anti-TNFR2 mAb treatment were evaluated as well as the effect on tumor progression., Results: Patients with PDAC exhibited elevated TNFR2 expression in Treg, myeloid cells and endothelial cells and lower level in tumor cells. By flow cytometry and single-cell RNA-seq analysis, we identified two Treg populations in orthotopic mouse models: Resting and activated Tregs. The anti-TNFR2 mAb selectively targeted activated tumor-infiltrating Tregs, reducing T cell exhaustion markers in CD8
+ T cells. However, anti-TNFR2 treatment alone had limited efficacy in activating CD8+ T cells and only slightly reduced the tumor growth. The combination of the anti-TNFR2 mAb with agonistic anti-CD40 mAb promoted stronger T cell activation, tumor growth inhibition, and improved survival and immunological memory in PDAC-bearing mice., Conclusion: Our data suggest that combining a CD40 agonist with a TNFR2 antagonist represents a promising therapeutic strategy for patients with PDAC., Competing Interests: Competing interests: EP is co-founder and consultant for Egle-Tx., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2024
- Full Text
- View/download PDF
33. PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination.
- Author
-
Franzolin G, Brundu S, Cojocaru CF, Curatolo A, Ponzo M, Mastrantonio R, Mihara E, Kumanogoh A, Suga H, Takagi J, Tamagnone L, and Giraudo E
- Subjects
- Animals, Female, Mice, Humans, Nerve Tissue Proteins genetics, Nerve Tissue Proteins metabolism, Cell Line, Tumor, Breast Neoplasms immunology, Breast Neoplasms pathology, Breast Neoplasms metabolism, Breast Neoplasms genetics, Receptors, Cell Surface metabolism, Receptors, Cell Surface genetics, Tumor-Associated Macrophages immunology, Tumor-Associated Macrophages metabolism, Neoplasm Metastasis, Mice, Knockout, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Triple Negative Breast Neoplasms immunology, Triple Negative Breast Neoplasms pathology, Triple Negative Breast Neoplasms metabolism, CD8-Positive T-Lymphocytes immunology, Semaphorins genetics, Tumor Microenvironment immunology
- Abstract
Semaphorin-plexin signaling plays a major role in the tumor microenvironment (TME). In particular, Semaphorin 4D (SEMA4D) has been shown to promote tumor growth and metastasis; however, the role of its high-affinity receptor Plexin-B1 (PLXNB1), which is expressed in the TME, is poorly understood. In this study, we directly targeted PLXNB1 in the TME of triple-negative murine breast carcinoma to elucidate its relevance in cancer progression. We found that primary tumor growth and metastatic dissemination were strongly reduced in PLXNB1-deficient mice, which showed longer survival. PLXNB1 loss in the TME induced a switch in the polarization of tumor-associated macrophages (TAM) toward a pro-inflammatory M1 phenotype and enhanced the infiltration of CD8+ T lymphocytes both in primary tumors and in distant metastases. Moreover, PLXNB1 deficiency promoted a shift in the Th1/Th2 balance of the T-cell population and an antitumor gene signature, with the upregulation of Icos, Perforin-1, Stat3, and Ccl5 in tumor-infiltrating lymphocytes (TILs). We thus tested the translational relevance of TME reprogramming driven by PLXNB1 inactivation for responsiveness to immunotherapy. Indeed, in the absence of PLXNB1, the efficacy of anti-PD-1 blockade was strongly enhanced, efficiently reducing tumor growth and distant metastasis. Consistent with this, pharmacological PLXNB1 blockade by systemic treatment with a specific inhibitor significantly hampered breast cancer growth and enhanced the antitumor activity of the anti-PD-1 treatment in a preclinical model. Altogether, these data indicate that PLXNB1 signaling controls the antitumor immune response in the TME and highlight this receptor as a promising immune therapeutic target for metastatic breast cancers., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
34. Progression of the ascending aorta diameter after surgical or transcatheter bicuspid aortic valve replacement.
- Author
-
Chiariello GA, Di Mauro M, Pasquini A, Bruno P, Nesta M, Fabiani L, Mazza A, Meloni M, Baldo E, Ponzo M, Ferraro F, Conserva AD, D'Acierno E, Villa E, Trani C, Burzotta F, and Massetti M
- Abstract
Objectives: Ascending aorta (AA) dilatation in patients with bicuspid aortic valve (AV) is related both to genetic and haemodynamic factors. The aim of this study is to compare late progression of AA dilatation in bicuspid AV patients undergoing surgical aortic valve replacement (SAVR) versus transcatheter aortic valve implantation (TAVI)., Methods: Data of 189 consecutive patients who underwent AV replacement for severe bicuspid AV stenosis were prospectively collected. Patients who underwent SAVR were compared to patients who underwent TAVI. Indication to the procedure was validated by the institutional Heart Team. Aortic diameters were evaluated by transthoracic echocardiogram. Differences between preoperative and long-term follow-up AA diameters were compared in the 2 groups., Results: Between January 2015 and December 2021, 143 (76%) patients underwent SAVR and 46 (24%) patients underwent TAVI. At 4.6 (standard deviation 1.7) years follow-up, patients in the TAVI group showed significantly lower survival (P = 0.00013) and event-free survival (P < 0.0001). AA diameter progression was lower in surgical compared to transcatheter patients, 0.95 (0.60, 1.30) vs 1.65 (0.67, 2.63) mm, P = 0.02. AA diameter progression indexed for body surface area and height was lower in the surgical group: 0.72 (0.38, 1.05) vs 1.05 (0.39, 1.71) mm/m2, P = 0.02, and 0.59 (0.36, 0.81) vs 1.11 (0.44, 1.78) mm/m, P = 0.001, respectively. At multivariable linear regression analysis transcatheter procedure, baseline aortic diameter and paravalvular leak were significantly associated with increased postoperative AA dilatation., Conclusions: Bicuspid AV patients who underwent SAVR, showed significantly less long-term AA diameter progression than patients who underwent transcatheter procedure., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)
- Published
- 2024
- Full Text
- View/download PDF
35. Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide.
- Author
-
Matteo C, Orienti I, Eramo A, Zeuner A, Ferrari M, Passoni A, Bagnati R, Ponzo M, Bello E, Zucchetti M, and Frapolli R
- Abstract
We describe the development and validation of a HPLC-MS/MS method to assess the pharmacokinetics and tumor distribution of fenretinide, a synthetic retinoid chemically related to all-trans-retinoic acid, after administration of a novel oral nanoformulation of fenretinide, called bionanofenretinide (BNF). BNF was developed to overcome the major limitation of fenretinide: its poor aqueous solubility and bioavailability due to its hydrophobic nature. The method proved to be reproducible, precise and highly accurate for the measurement of the drug and the main metabolites. The lower limit of quantification resulted in 1 ng/mL. The curve range of 1-500 ng/mL and 50-2000 ng/mL, for plasma and tumor homogenate, respectively, was appropriate for the analysis, as demonstrated by the accuracy of between 96.8% and 102.4% for plasma and 96.6 to 102.3% for the tumor. The interdays precision and accuracy determined on quality controls at three different levels were in the ranges of 6.9 to 7.5% and 99.3 to 101.0%, and 0.96 to 1.91% and 102.3 to 105.8% for plasma and tumor, respectively. With the application of the novel assay in explorative pharmacokinetic studies, following acute and chronic oral administration of the nanoformulation, fenretinide was detected in plasma and tumor tissue at a concentration higher than the IC50 value necessary for in vitro inhibitory activity (i.e., 1-5 µM) in different cancer cells lines. We were also able to detect the presence in plasma and tumor of active and inactive metabolites of fenretinide.
- Published
- 2024
- Full Text
- View/download PDF
36. Complications in endoscopic spine surgery: a systematic review.
- Author
-
Compagnone D, Mandelli F, Ponzo M, Langella F, Cecchinato R, Damilano M, Redaelli A, Peretti GM, Vanni D, and Berjano P
- Subjects
- Humans, Databases, Factual, Lumbosacral Region, Diskectomy, Endoscopy adverse effects, Spine surgery
- Abstract
Purpose: This systematic review aims to investigate the complication rate of endoscopic spine surgeries, stratifying them by technique, district and kind of procedure performed., Methods: This study was conducted according to the PRISMA statement. The literature search was conducted in MEDLINE, CINAHL, EMBASE, Cochrane Register, OTseeker and ScienceDirect database. Types of studies included were observational studies (cohort studies, case-control studies and case series) and randomised or quasi-randomised clinical with human subjects. No restrictions on publication year were applied. Repeated articles, reviews, expert's comments, congress abstracts, technical notes and articles not in English were excluded. Several data were extracted from the articles. In particular, data of perioperative (≤ 3 months) and late (> 3 months) complications were collected and grouped according to: (1) surgical technique [uniportal full-endoscopic spine surgery (UESS) or unilateral biportal endoscopic spine surgery (UBESS)]; (2) spinal district treated [cervical, thoracic or lumbar] and (3) type of procedure [discectomy/decompression or fusion]. Complication analysis was performed in subgroups with at least 100 patients to have clinically meaningful statistical validity., Results: A total of 117 full-text articles were assessed for eligibility. Of the 117 records included, 95 focused their research on UESS (14 LOE V, 33 LOE IV, 43 LOE III and five LOE II) and 23 on UBESS (three LOE V, eight LOE IV, 10 LOE III and two LOE II). A total of 20,020 patients were extracted to investigate the incidence of different perioperative and late complications, 10,405 for UESS and 9615 for UBESS., Conclusion: The present study summarises the complications reported in the literature for spinal endoscopic procedures. On the one hand, the most relevant described were perioperative complications (transient neurological deficit, dural tear and dysesthesia) that are especially meaningful for endoscopic discectomy and decompression. On the other hand, late complications, such as mechanical implant failure, are more common in endoscopic interbody fusion., Level of Evidence: I., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
37. Assessment of deep plane facelift combined with fascia lata graft for the static treatment of facial palsy: A preliminary report.
- Author
-
La Padula S, Ponzo M, Lombardi M, de Gregorio L, D'Andrea F, Coiante E, Pensato R, Hersant B, and Meningaud JP
- Subjects
- Aged, Humans, Child, Preschool, Child, Adolescent, Young Adult, Adult, Middle Aged, Fascia Lata transplantation, Prospective Studies, Reproducibility of Results, Pilot Projects, Facial Paralysis surgery, Rhytidoplasty, Bell Palsy
- Abstract
Addressing facial palsy (FP) presents intricate challenges in achieving natural expressions. Although free functional muscle transfers (FFMT) offer effective smile restoration, age impacts their efficacy. The optimal FFMT age range of 5-55 years is limited by physical fitness, which extends beyond age boundaries. Unilateral FP demands vary; younger patients require dynamic solutions like FFMT, whereas older individuals prioritize public appearance due to baseline distortion. The aim of this study is to describe and to assess a new static technique combining deep plane facelift and fascia lata graft for FP treatment. We conducted a prospective pilot study enrolling unilateral FP patients aged >55 and declining FFMT. Exclusions encompassed prior FP surgery, recent injections, uncontrolled diabetes cognitive deficits, and patients unable to quit smoking. To evaluate this technique, the Glasgow Benefit Inventory (GBI), along with two objective scales, the Face- and Neck-Lift Objective Photo-Numerical Assessment Scale and the eFACE scale, were used. Interrater reliability and intrarater reliability were assessed. Fifteen patients (mean age: 60.9 years) underwent the procedure. Both static and dynamic symmetry significantly improved (p < 0.05), including check volume and position, oral commissure, and jawline. Notably, eye closure enhancement was observed. GBI scores also significantly increased (p < 0.05). Interrater reliability and intrarater reliability were minimal (p = 0.12 and p = 0.13). This combined approach offers a static FP treatment option, especially for the elderly or FFMT-ineligible patients. The relatively brief procedure yields immediate and satisfactory results, suggesting its potential value in FP management. Further comprehensive studies are encouraged to validate the technique's long-term efficacy and applicability across larger populations., (Copyright © 2023 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. GLUT-1/PKM2 loop dysregulation in patients with non-ST-segment elevation myocardial infarction promotes metainflammation.
- Author
-
Canonico F, Pedicino D, Severino A, Vinci R, Flego D, Pisano E, d'Aiello A, Ciampi P, Ponzo M, Bonanni A, De Ciutiis A, Russo S, Di Sario M, Angelini G, Szczepaniak P, Baldi A, Kapelak B, Wierzbicki K, Montone RA, D'Amario D, Massetti M, Guzik TJ, Crea F, and Liuzzo G
- Subjects
- Humans, Adaptive Immunity, Glucose, Inflammation, Non-ST Elevated Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction
- Abstract
Aims: The functional capacity of the immune cells is strongly dependent on their metabolic state and inflammatory responses are characterized by a greater use of glucose in immune cells. This study is aimed to establish the role of glucose metabolism and its players [glucose transporter 1 (GLUT-1) and pyruvate kinase isozyme M2 (PKM2)] in the dysregulation of adaptive immunity and inflammation observed in patients with non-ST-segment elevation myocardial infarction (NSTEMI)., Methods and Results: We enrolled 248 patients allocated to three groups: NSTEMI patients, chronic coronary syndromes (CCS) patients, healthy subjects (HSs). NSTEMI patients showed higher expression of GLUT-1 and an enhanced glucose uptake in T cells when compared with CCS patients (P < 0.0001; P = 0.0101, respectively) and HSs (P = 0.0071; P = 0.0122, respectively). PKM2 had a prevalent nuclear localization in T lymphocytes in NSTEMI (P = 0.0005 for nuclear vs. cytoplasm localization), while in CCS and HS, it was equally distributed in both compartments. In addition, the nuclear fraction of PKM2 was significantly higher in NSTEMI compared with HS (P = 0.0023). In NSTEMI patients, treatment with Shikonin and Fasentin, which inhibits PKM2 enzyme activity and GLUT-1-mediated glucose internalization, respectively, led to a significant reduction in GLUT-1 expression along with the down-regulation of pro-inflammatory cytokine expression., Conclusion: NSTEMI patients exhibit dysregulation of the GLUT-1/PKM2 metabolic loop characterized by nuclear translocation of PKM2, where it acts as a transcription regulator of pro-inflammatory genes. This detrimental loop might represent a new therapeutic target for personalized medicine., Competing Interests: Conflict of interest: F.Cr. reports speaker fees from Amgen, Astra Zeneca, Servier, BMS, other from GlyCardial Diagnostics, outside the submitted work. G.L. received grant support (to the institution) for investigator-initiated research from American Heart Association, Italian National Health Service, and Italian Minister of Education, University and Research. She is currently involved in the Research Programs of the Italian Cardiovascular Network. She received personal fees from Astra Zeneca, Boehringer Ingelheim, Novo Nordisk, Daiichi Sankyo, Sanofi, and Novartis, outside the submitted work., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
39. The influence of peri-operative depressive symptoms on medium-term spine surgery outcome: a prospective study.
- Author
-
Bellosta-López P, Mandelli F, Langella F, Brayda-Bruno M, Bassani R, Cecchinato R, Compagnone D, Giudici F, Luca A, Morselli C, Scaramuzzo L, Vanni D, Ponzo M, and Berjano P
- Subjects
- Humans, Prospective Studies, Treatment Outcome, Quality of Life, Depression epidemiology, Depression complications, Disability Evaluation
- Abstract
Purpose: To investigate the role of depressive symptoms on clinical outcomes in patients undergoing spinal surgery up to 2-year follow-up., Methods: The study used data from an institutional spine surgery registry (January 2016, through March 2022) to identify patients (> 18 years) undergoing spine surgery. Patients with Oswestry Disability Index (ODI) < 20/100 at baseline or undergoing surgery on the cervical spine or for idiopathic spinal deformity and trauma patients were excluded. The patients were divided into two groups based on the pre-operative Mental Component Summary (MCS) score of the SF-36: depression group (MCS ≤ 35) or non-depression group (MCS > 35). The ODI and MCS scores trajectory were wined over the 24-month post-surgery between groups. Additionally, a secondary subgroup analysis was conducted comparing outcomes between those with depressive symptoms (persistent-depression subgroup) and those without depressive symptoms (never-depression subgroup) at 3 months after surgery., Results: A total of 2164 patients who underwent spine surgery were included. The pre-operative depression group reported higher ODI total scores and lower MCS than the pre-operative non-depression group at all time points (P < 0.001). The persistent-depression subgroup reported higher ODI total scores and lower MCS than the never-depression subgroup at all follow-ups (P < 0.001)., Conclusion: Functional disability and mental health status improve in patients with depression symptoms undergoing spinal surgery. Despite this improvement, they do not reach the values of non-depressed subjects. Over the 2-year follow-up time, patients with depression show a different trajectory of ODI and MCS. Caregivers should be aware of these results to counsel patients with depression symptoms., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
40. Microbial signature of plaque and gut in acute coronary syndrome.
- Author
-
Pisano E, Bugli F, Severino A, Pedicino D, Paroni Sterbini F, Martini C, De Maio F, Vinci R, Sacconi A, Canonico F, D'Aiello A, Bonanni A, Proto L, Ciampi P, Ponzo M, Grimaldi MC, Urbani A, Primiano A, Gervasoni J, Montone R, Crea F, Sanguinetti M, and Liuzzo G
- Subjects
- Humans, RNA, Ribosomal, 16S genetics, Heart, Acute Coronary Syndrome, Angioplasty, Balloon, Carnobacteriaceae
- Abstract
Gut microbiota is an emerging editable cardiovascular risk factor. We aim to investigate gut and coronary plaque microbiota, using fecal samples and angioplasty balloons from patients with acute coronary syndrome (ACS), chronic coronary syndrome (CCS) and control subjects. We examined bacterial communities in gut and coronary plaques by 16S rRNA sequencing and we performed droplet digital PCR analysis to investigate the gut relative abundance of the bacterial genes CutC/CntA involved in trimethylamine N-oxide synthesis. Linear discriminant analysis effect size (LEfSe) at the genus and species levels displayed gut enrichment in Streptococcus, Granulicatella and P. distasonis in ACS compared with CCS and controls; Roseburia, C. aerofaciens and F. prausnitzii were more abundant in controls than in patients. Principal component analysis (PCA) of 41 differentially abundant gut taxa showed a clustering of the three groups. In coronary plaque, LEfSe at the genus level revealed an enrichment of Staphylococcus and Streptococcus in ACS, and Paracoccus in CCS, whereas PCA of 15 differentially abundant plaque taxa exhibited clustering of ACS and CCS patients. CutC and CntA genes were more abundant in ACS and CCS than in controls while no significant difference emerged between ACS and CCS. Our results indicate that ACS and CCS exhibit a different gut and plaque microbial signature, suggesting a possible role of these microbiotas in coronary plaque instability., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
41. Erratum: Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.
- Author
-
Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, Manfredi F, Pellegrino C, Pascolo S, Miskey C, Sandoval-Villegas N, Ivics Z, Shizuru JA, Neri D, and Manz MG
- Abstract
[This corrects the article DOI: 10.1016/j.omto.2023.07.003.]., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
42. Delayed Intracerebral Hematoma after Ventriculoperitoneal Shunt in the Context of Ruptured Brain Arteriovenous Malformation: A Literature Review.
- Author
-
Dannhoff G, Chibbaro S, Mallereau CH, Ganau M, Agbo-Ponzo M, Santin MDN, Ollivier I, Pop R, Proust F, and Todeschi J
- Abstract
Hemorrhagic complications arising from ventricular drainage procedures are typically asymptomatic and of low volume. A particular subset of these complications, known as delayed intracranial hemorrhage (DICH), is however recognized for its particularly poor prognosis. We primarily aimed to identify epidemiological characteristics associated with DICH, to shed light on its occurrence and potential risk factors. To do so, we performed a retrospective analysis of a series of ten patients who presented with DICH in the context of a ruptured brain arteriovenous malformation (bAVM) and a systematic literature review of all DICH cases reported in the literature. Our ten patients showed delayed neurological deterioration after a ventriculoperitoneal shunt (VPS) procedure, with a computed tomography (CT) scan revealing a DICH surrounding the ventricular catheter, distinct and away from the nidus of their previously ruptured bAVM. Four patients (40%) rapidly declined and passed away, three (30%) required surgical management and the remaining three (30%) demonstrated gradual clinical improvement with conservative management. In the literature, most patients presenting with DICH had hydrocephalus associated with neurovascular disorders (47% of cases), such as bAVM rupture in our present series. These constatations point out the significance of the underlying pathologies potentially being predisposed to these unusual complications.
- Published
- 2023
- Full Text
- View/download PDF
43. The burden of preoperative fear-avoidance beliefs in workers after thoracic and lumbar spine surgery: a 2-year follow-up study.
- Author
-
Bellosta-López P, Langella F, Ponzo M, Bassani R, Brayda-Bruno M, Damilano M, Giudici F, Lovi A, Morselli C, Redaelli A, Scaramuzzo L, Lamartina C, and Berjano P
- Subjects
- Humans, Female, Follow-Up Studies, Surveys and Questionnaires, Return to Work, Disability Evaluation, Fear psychology, Employment
- Abstract
Abstract: Spinal disorders are the main reasons for sick leave and early retirement among the working population in industrialized countries. When "red flags" are present, spine surgery is the treatment of choice. However, the role of psychosocial factors such as fear-avoidance beliefs in spine surgery outcomes is still debated. The study aims to investigate whether patients presenting high or low levels of fear-avoidance thoughts before the spine surgery reported different surgical results and return-to-work rates over 2 years. From an institutional spine surgery registry, workers surgically treated with a preoperative score in the Oswestry Disability Index (ODI) higher than 20/100 and provided ODI questionnaires, return-to-work status at 3-, 6-, 12-, and 24-month follow-ups were analyzed. A total of 1769 patients were stratified according to the work subscale of the Fear-Avoidance Beliefs Questionnaire (FABQ-W) in high fear (FABQ-W ≥ 34/42) or low fear (FABQ-W < 34/42). Multivariate regression was used to search for preoperative factors, which might interact with FABQ-W. The higher-fear group showed a different recovery pattern, with higher levels of disability according to the ODI (total score, absolute change, frequency of clinically relevant change, and disability categories) and lower return-to-work ratios over the 24-month follow-up. High fear, high disability, greater age, female gender, smoking, and worse physical status at baseline were associated with worse ODI outcomes 2 years after the surgery. In summary, fear-avoidance beliefs significantly influence the speed and the entity of surgical outcomes in the working population. However, the contribution of FABQ-W in predicting long-term disability levels was limited., (Copyright © 2023 International Association for the Study of Pain.)
- Published
- 2023
- Full Text
- View/download PDF
44. Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.
- Author
-
Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, Manfredi F, Pellegrino C, Pascolo S, Miskey C, Ivics Z, Shizuru JA, Neri D, and Manz MG
- Abstract
Discrimination between hematopoietic stem cells and leukemic stem cells remains a major challenge for acute myeloid leukemia immunotherapy. CAR T cells specific for the CD117 antigen can deplete malignant and healthy hematopoietic stem cells before consolidation with allogeneic hematopoietic stem cell transplantation in absence of cytotoxic conditioning. Here we exploit non-viral technology to achieve early termination of CAR T cell activity to prevent incoming graft rejection. Transient expression of an anti-CD117 CAR by mRNA conferred T cells the ability to eliminate CD117+ targets in vitro and in vivo . As an alternative approach, we used a Sleeping Beauty transposon vector for the generation of CAR T cells incorporating an inducible Caspase 9 safety switch. Stable CAR expression was associated with high proportion of T memory stem cells, low levels of exhaustion markers, and potent cellular cytotoxicity. Anti-CD117 CAR T cells mediated depletion of leukemic cells and healthy hematopoietic stem cells in NSG mice reconstituted with human leukemia or CD34+ cord blood cells, respectively, and could be terminated in vivo . The use of a non-viral technology to control CAR T cell pharmacokinetic properties is attractive for a first-in-human study in patients with acute myeloid leukemia prior to hematopoietic stem cell transplantation., Competing Interests: The authors declare no competing interests., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
45. Nanofat in Plastic Reconstructive, Regenerative, and Aesthetic Surgery: A Review of Advancements in Face-Focused Applications.
- Author
-
La Padula S, Ponzo M, Lombardi M, Iazzetta V, Errico C, Polverino G, Russo F, D'Andrea L, Hersant B, Meningaud JP, Salzano G, and Pensato R
- Abstract
Nanofat is a relatively novel technique in fat grafting that has gained significant interest in the fields of regenerative medicine, aesthetic and translational research. It involves the extraction of autologous fat from a patient, which is then transformed into "nanofat", consisting of small fat particles with a diameter of less than 0.1 mm and containing high concentrations of stem cells and growth factors. This article focuses on the use of nanofat in facial rejuvenation and its potential for lipomodelling. Fat tissue is a "stem cell depot" and nanofat contains many stem cells that can differentiate into various cell types. The Lipogem technology, developed in 2013, enables the isolation of nanofat with an intact perivascular structure, utilizing the high concentration of mesenchymal stromal cells near the pericytes of the adipose vascular system. Nowadays nanofat is used primarily for cosmetic purposes particularly in rejuvenating and improving the appearance of the skin, especially the face. Indeed, it has wide applicability; it can be used to treat fine lines, wrinkles, acne scars, sun-damaged skin, scar repair, and as an alopecia treatment. However, further studies are needed to assess the long-term efficacy and safety of this technique. In conclusion, nanofat is a safe and minimally invasive option for tissue regeneration with considerable therapeutic potential. This study reviews the application and effects of nanofat in regenerative medicine and facial cosmetic surgery.
- Published
- 2023
- Full Text
- View/download PDF
46. Comments on: "The influence of spine-hip relations on total hip replacement: A systematic review" of C. Rivière, J. -Y. Lazennec, C. Van Der Straeten, E. Auvinet, J. Cobb, S. Muirhaed-Allwood published in Orthop Traumatol Surg Res 2017 Jun;103(4):559-568.
- Author
-
Vanni D, Compagnone D, Ponzo M, Langella F, and Berjano P
- Subjects
- Humans, Spine, Arthroplasty, Replacement, Hip
- Published
- 2023
- Full Text
- View/download PDF
47. Oblique, Unilateral, or Bilateral Rods Configurations for Single-Level Interbody Fusion and Posterior Spinal Fixation: A Finite Element Study.
- Author
-
Redaelli A, Panico M, Cecchinato R, Damilano M, Vanni D, Ponzo M, Galbusera F, and Langella F
- Subjects
- Finite Element Analysis, Biomechanical Phenomena, Range of Motion, Articular, Lumbar Vertebrae diagnostic imaging, Lumbar Vertebrae surgery, Pedicle Screws
- Abstract
Aim: To compare three different posterior mono-segmental instrumented models with a Lateral Lumbar Interbody Fusion (LLIF) cage in L4-L5 based on finite element (FE) analysis., Material and Methods: Three different configurations of posterior instrumentation were created: 1. Bilateral posterior screws with 2 rods: Bilateral (B); 2. Left posterior rod and left pedicle screws in L4-L5: Unilateral (U); 3. Oblique posterior rod, left pedicle screw in L4, and right pedicle screw in L5: Oblique (O). The models were compared regarding the range of motion (ROM), stresses in the L4 and L5 pedicle screws, and posterior rods., Results: The Oblique and Unilateral models showed a lower decrease in ROM than the Bilateral model (O vs U vs B; 92% vs 95% vs 96%). In the L4 screw, a higher stress level was identified in the O than in the B model. Still, lower if compared to U. In the L5 screw, the highest stress values were observed with the O model in extension and flexion and the U model in lateral bending and axial rotation. The highest stress values for the rods were observed for the O model in extension, flexion, and axial rotation and the U model in lateral bending., Conclusion: The FE analysis showed that the three configurations significantly reduced the ROM. The stress analysis identified a substantially higher value for the rod and pedicle screws in oblique or unilateral configuration systems compared to the standard bilateral one. In particular, the oblique configuration has stress properties similar to the unilateral in lateral bending and axial rotation but is significantly higher in flexion-extension.
- Published
- 2023
- Full Text
- View/download PDF
48. Coronary artery plaque rupture and erosion: Role of wall shear stress profiling and biological patterns in acute coronary syndromes.
- Author
-
Russo G, Pedicino D, Chiastra C, Vinci R, Lodi Rizzini M, Genuardi L, Sarraf M, d'Aiello A, Bologna M, Aurigemma C, Bonanni A, Bellantoni A, D'Ascenzo F, Ciampi P, Zambrano A, Mainardi L, Ponzo M, Severino A, Trani C, Massetti M, Gallo D, Migliavacca F, Maisano F, Lerman A, Morbiducci U, Burzotta F, Crea F, and Liuzzo G
- Subjects
- Humans, Coronary Vessels pathology, Leukocytes, Mononuclear, Tomography, Optical Coherence methods, Rupture, Spontaneous metabolism, Rupture, Spontaneous pathology, Coronary Angiography methods, Galectins metabolism, Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome genetics, Plaque, Atherosclerotic diagnostic imaging, Plaque, Atherosclerotic genetics, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease genetics, Heart Rupture
- Abstract
Aims: Wall shear stress (WSS) is involved in coronary artery plaque pathological mechanisms and modulation of gene expression. This study aims to provide a comprehensive haemodynamic and biological description of unstable (intact-fibrous-cap, IFC, and ruptured-fibrous-cap, RFC) and stable (chronic coronary syndrome, CCS) plaques and investigate any correlation between WSS and molecular pathways., Methods and Results: We enrolled 24 CCS and 25 Non-ST Elevation Myocardial Infarction-ACS patients with IFC (n = 11) and RFC (n = 14) culprit lesions according to optical coherence tomography analysis. A real-time PCR primer array was performed on peripheral blood mononuclear cells for 17 different molecules whose expression is linked to WSS. Computational fluid dynamics simulations were performed in high-fidelity 3D-coronary artery anatomical models for three patients per group. A total of nine genes were significantly overexpressed in the unstable patients as compared to CCS patients, with no differences between IFC and RFC groups (GPX1, MMP1, MMP9, NOS3, PLA2G7, PI16, SOD1, TIMP1, and TFRC) while four displayed different levels between IFC and RFC groups (TNFα, ADAMTS13, EDN1, and LGALS8). A significantly higher WSS was observed in the RFC group (p < 0.001) compared to the two other groups. A significant correlation was observed between TNFα (p < 0.001), EDN1 (p = 0.036), and MMP9 (p = 0.005) and WSS values in the RFC group., Conclusions: Our data demonstrate that IFC and RFC plaques are subject to different WSS conditions and gene expressions, suggesting that WSS profiling may play an essential role in the plaque instability characterization with relevant diagnostic and therapeutic implications in the era of precision medicine., (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
49. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022 , 14 , 4265.
- Author
-
Ponzo M, Debesset A, Cossutta M, Chalabi-Dchar M, Houppe C, Pilon C, Nicolas-Boluda A, Meunier S, Raineri F, Thiolat A, Nicolle R, Maione F, Brundu S, Cojocaru CF, Bouvet P, Bousquet C, Gazeau F, Tournigand C, Courty J, Giraudo E, Cohen JL, and Cascone I
- Abstract
In the original publication [...].
- Published
- 2022
- Full Text
- View/download PDF
50. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression.
- Author
-
Ponzo M, Debesset A, Cossutta M, Chalabi-Dchar M, Houppe C, Pilon C, Nicolas-Boluda A, Meunier S, Raineri F, Thiolat A, Nicolle R, Maione F, Brundu S, Cojocaru CF, Bouvet P, Bousquet C, Gazeau F, Tournigand C, Courty J, Giraudo E, Cohen JL, and Cascone I
- Abstract
Background: The pancreatic ductal adenocarcinoma (PDAC) microenvironment is highly fibrotic and hypoxic, with poor immune cell infiltration. Recently, we showed that nucleolin (NCL) inhibition normalizes tumour vessels and impairs PDAC growth. Methods: Immunocompetent mouse models of PDAC were treated by the pseudopeptide N6L, which selectively inhibits NCL. Tumour-infiltrating immune cells and changes in the tumour microenvironment were analysed. Results: N6L reduced the proportion of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) and increased tumour-infiltrated T lymphocytes (TILs) with an activated phenotype. Low-dose anti-VEGFR2 treatment normalized PDAC vessels but did not modulate the immune suppressive microenvironment. RNAseq analysis of N6L-treated PDAC tumours revealed a reduction of cancer-associated fibroblast (CAF) expansion in vivo and in vitro. Notably, N6L treatment decreased IL-6 levels both in tumour tissues and in serum. Treating mPDAC by an antibody blocking IL-6 reduced the proportion of Tregs and MDSCs and increased the amount of TILs, thus mimicking the effects of N6L. Conclusions: These results demonstrate that NCL inhibition blocks the amplification of lymphoid and myeloid immunosuppressive cells and promotes T cell activation in PDAC through a new mechanism of action dependent on the direct inhibition of the tumoral stroma.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.